The present preclinical study aimed to characterize the benefits and molecular mechanisms of combination therapy with zalfermin and semaglutide in the amylin liver nonalcoholic steatohepatitis (AMLN) diet-induced obese (DIO)-MASH mouse, a translational model of biopsy-confirmed MASH and fibrosis [19,20], with emphasis on clinically relevant endpoints and liver transcriptome changes. This evidence concerns the gene IAPP and metabolic dysfunction-associated steatohepatitis.